CrystalGenomics has already secured several partnership deals where it would be eligible to receive milestones and royalties. The notable cases include a joint venture deal with ProQuest Investments in 2008 based on an oral anemia treatment program which is worth up to $200 million, and recent research collaboration and license agreement with AstraZeneca.

Commenting on long-term goal, Dr Joong Myung Cho says, "Our ultimate goal is to become a full-spectrum pharmaceutical company with our own products in the market without losing competitiveness in the discovery area that has played a crucial part in propelling CrystalGenomics' phenomenal growth so far."

Sharing his views on receiving the BioSpectrum Asia Pacific Emerging Company of the Year 2010 Award, Dr Joong Myung Cho, says, "We are honored to be one of the recipients of this prestigious award and believe that this is another validation of our capabilities and potential. Although we are satisfied with our track record so far, there is still a long way to go and we will strive to be the best company that we can be."

"Our competitors include companies outside Asia, and therefore, we view this industry as being highly competitive. The fact that CrystalGenomics has been able to thrive in this recently depressed industry may have demonstrated our competitiveness, however, we plan to raise the bar even higher moving forward," he concludes on a positive note.